The global newborn screening market is projected to reach $2.49 billion by 2030, at a CAGR of 7.9% from 2023 to 2030.
Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by the rising prevalence of congenital heart diseases and genetic disorders, the increasing neonatal population, and the rising awareness regarding newborn screening.
Furthermore, emerging economies and government programs & legislation promoting newborn screening provide a significant growth opportunity for this market. However, the shortage of healthcare professionals and the emergence of non-invasive prenatal screening technologies may restrain the growth of this market. Additionally, ethical concerns related to newborn screening and the high costs of genomic newborn testing pose a major challenge for the players operating in this market.
Among products, in 2023, the consumables segment is expected to account for the largest share of the newborn screening market. The large market share of this segment is attributed to the increased demand for consumables for newborn screening, repeat purchases of consumables for newborn screening and the availability of advanced kits.
Among technologies, in 2023, the tandem mass spectrometry segment is expected to account for the largest share of the newborn screening market. The increasing prevalence of genetic disorders, cost-effectiveness, high applicability, short turnaround time, ability to screen multiple diseases simultaneously, and technological advancements are expected to boost the growth of this segment.
Among applications, in 2023, the inherited disorders segment is expected to account for the largest share of the newborn screening market. The large market share of this segment is attributed to factors such as the high prevalence of inherited disorders among newborns, variations and mutations in the genes, inherited gene defects, and abnormality in genetic composition.
Among end users, in 2023, the hospitals segment is expected to account for the largest share of the newborn screening market. The large market share of this segment is attributed to factors such as the high preference for hospitals as childbirth facilities, the growing newborn population, continuous improvements in healthcare infrastructure, utilization of advanced techniques, and the availability of skilled professionals.
An in-depth analysis of the geographical scenario of the global newborn screening market provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America) along with the coverage of major countries in each region.
In 2023, North America is expected to account for the largest share of the global newborn screening market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Asia-Pacific is expected to be the fastest-growing region of the global newborn screening market.
The key players operating in the global newborn screening market are Thermo Fisher Scientific, Inc. (U.S.), ARCHIMED Group (France), PerkinElmer, Inc. (U.S.), Medtronic plc (Ireland), Trivitron Healthcare Pvt Ltd. (India), Bio-Rad Laboratories, Inc. (U.S.), Demant A/S (Denmark), Baebies, Inc. (U.S.), ZenTech s.a. (Belgium), and F. Hoffmann-La Roche AG (Switzerland).
Note: Other applications include birth injuries, birth trauma, and malformation.
Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by the rising prevalence of congenital heart diseases and genetic disorders, the increasing neonatal population, and the rising awareness regarding newborn screening.
Furthermore, emerging economies and government programs & legislation promoting newborn screening provide a significant growth opportunity for this market. However, the shortage of healthcare professionals and the emergence of non-invasive prenatal screening technologies may restrain the growth of this market. Additionally, ethical concerns related to newborn screening and the high costs of genomic newborn testing pose a major challenge for the players operating in this market.
Among products, in 2023, the consumables segment is expected to account for the largest share of the newborn screening market. The large market share of this segment is attributed to the increased demand for consumables for newborn screening, repeat purchases of consumables for newborn screening and the availability of advanced kits.
Among technologies, in 2023, the tandem mass spectrometry segment is expected to account for the largest share of the newborn screening market. The increasing prevalence of genetic disorders, cost-effectiveness, high applicability, short turnaround time, ability to screen multiple diseases simultaneously, and technological advancements are expected to boost the growth of this segment.
Among applications, in 2023, the inherited disorders segment is expected to account for the largest share of the newborn screening market. The large market share of this segment is attributed to factors such as the high prevalence of inherited disorders among newborns, variations and mutations in the genes, inherited gene defects, and abnormality in genetic composition.
Among end users, in 2023, the hospitals segment is expected to account for the largest share of the newborn screening market. The large market share of this segment is attributed to factors such as the high preference for hospitals as childbirth facilities, the growing newborn population, continuous improvements in healthcare infrastructure, utilization of advanced techniques, and the availability of skilled professionals.
An in-depth analysis of the geographical scenario of the global newborn screening market provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America) along with the coverage of major countries in each region.
In 2023, North America is expected to account for the largest share of the global newborn screening market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Asia-Pacific is expected to be the fastest-growing region of the global newborn screening market.
The key players operating in the global newborn screening market are Thermo Fisher Scientific, Inc. (U.S.), ARCHIMED Group (France), PerkinElmer, Inc. (U.S.), Medtronic plc (Ireland), Trivitron Healthcare Pvt Ltd. (India), Bio-Rad Laboratories, Inc. (U.S.), Demant A/S (Denmark), Baebies, Inc. (U.S.), ZenTech s.a. (Belgium), and F. Hoffmann-La Roche AG (Switzerland).
Scope of the Report:
Newborn Screening Market Assessment-by Product
- Instruments
- Consumables
Newborn Screening Market Assessment-by Technology
- Immune Assays & Enzymatic Assays
- Tandem Mass Spectrometry
- Molecular Assays
- Hearing Screening Technologies
- Pulse Oximetry
- Other Technologies
Newborn Screening Market Assessment-by Application
- Congenital Heart Disease
- Inherited Disorders
- Metabolic Disorders
- Endocrine Disorders
- Hemoglobin Disorders
- Other Inherited Disorders
- Infectious diseases
- Hearing Disorders
- Other Applications
Note: Other applications include birth injuries, birth trauma, and malformation.
Newborn Screening Market Assessment-by End User
- Hospitals
- Reference Laboratories
Newborn Screening Market Assessment-by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATM)
- Middle East & Africa
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Newborn Screening Market Assessment - by Product
6. Newborn Screening Market Assessment - by Technology
7. Newborn Screening Market Assessment - by Application
8. Newborn Screening Market Assessment - by End User
9. Newborn Screening Market Assessment - by Geography
10. Competition Analysis
11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
12. Appendix
List of Tables
List of Figures
Companies Mentioned
- Thermo Fisher Scientific Inc. (U.S.)
- ARCHIMED Group (France)
- PerkinElmer Inc. (U.S.)
- Medtronic plc (Ireland)
- Trivitron Healthcare Pvt Ltd. (India)
- Bio-Rad Laboratories Inc. (U.S.)
- Demant A/S (Denmark)
- Baebies Inc. (U.S.)
- ZenTech s.a. (Belgium)
- F. Hoffmann-La Roche AG (Switzerland)
